<div><div></div><div><span><p><span>Kiora Pharmaceuticals Inc reported results for the first quarter of fiscal 2026, posting a comprehensive loss of ($2.4M) and a net loss of ($2.42M), or diluted loss per share of ($0.58), compared with losses of ($2.21M), ($2.19M) and ($0.52) respectively in the prior-year quarter.</span></p><p><strong><span>Financial Highlights</span></strong></p><div><table><tbody><tr><td><span>Metric</span></td><td><span>Current quarter</span></td><td><span>Prior year quarter</span></td><td><span>YoY change</span></td></tr><tr><td><span>Revenue¹</span></td><td><span>($2.4M)</span></td><td><span>($2.21M)</span></td><td><span>(8.7%)</span></td></tr><tr><td><span>Net income²</span></td><td><span>($2.42M)</span></td><td><span>($2.19M)</span></td><td><span>(10.3%)</span></td></tr><tr><td><span>Diluted EPS³</span></td><td><span>($0.58)</span></td><td><span>($0.52)</span></td><td><span>(11.5%)</span></td></tr></tbody></table></div><p><em><span>¹ Reported as “Comprehensive Loss”. ² Reported as “Net Loss”. ³ Reported as “Loss per Common Share - Diluted”.</span></em></p><p><strong><span>Business Highlights</span></strong></p><ul><li><span>Partnership &amp; licensing: Executed an exclusive global license (ex-Asia) for KIO-301 with Théa Open Innovation, including $16M upfront plus potential milestones and royalties.</span></li><li><span>Clinical progress: Completed Phase 1b ABACUS-1 with positive topline and full data; Phase 2 ABACUS-2 initiated in 2025 with dosing underway.</span></li><li><span>Asian expansion option: Granted Senju an exclusive option for key Asian territories for KIO-301 with a $1.25M nonrefundable option fee and up to $109.5M plus royalties if exercised.</span></li><li><span>Pipeline: Advanced KIO-104 into Phase 2 for retinal inflammation; KIO-101 is paused and available for partnership.</span></li><li><span>Funding outlook: R&amp;D expenses for KIO-301 are largely reimbursed by the partner, with cash runway projected into late 2028 to support planned operations.</span></li></ul><p><span>Original SEC Filing: </span>KIORA PHARMACEUTICALS INC [ KPRX ] - 10-Q - May. 08, 2026</p><section><b><span class="heading-aHOVUrmQ">Disclaimer</span></b><div><span>This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.</span></div></section></span></div></div>

KPRX

ARKG

<p>Kiora Pharmaceuticals Inc reported its Q1 2026 results, showing a comprehensive loss of $2.4M and a net loss of $2.42M, with a diluted EPS of $0.58. This reflects a year-over-year increase in losses. The company executed a global license for KIO-301, received $16M upfront, and initiated Phase 2 trials for its pipeline products. R&D expenses are largely reimbursed, with cash runway projected into late 2028.</p>

TradingView

Kiora Pharmaceuticals

First Trust NYSE Arca Biotech Index Fd

Ark Genomic Revolution ETF

Health Care Select Sector SPDR

Proshares Ultra Nasdaq Biotech

ALPS Medical Breakthrough

VanEck Biotech ETF

iShares Biotechnology ETF

Direxion S&P Biotech Bull 3X

VG Health

iShares US Pharma

Invesco Biotechnology & Genome ETF

SPDR S&P Biotech

iShares Global Healthcare

Kiora Pharmaceuticals Inc 1Q 2026: Revenue ($2.4M), Net income ($2.42M), EPS ($0.58) — 10-Q Summary